Literature DB >> 19586712

Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice.

Jiann-Ming Wu1, Yun Chen, Jin-Cherng Chen, Tzu-Yu Lin, Sheng-Hong Tseng.   

Abstract

Tetrandrine, a bisbenzylisoquinoline alkaloid, exerts antitumor effects against some cancers. We explored tetrandrine's effects on colon cancer with cultured mouse CT-26 cells and with subcutaneous tumors. Tetrandrine induced apoptosis in concentration- and time-dependent manner. Tetrandrine increased expression of ERK 1/2 and p38 MAPK; inhibition of p38 MAPK reduced tetrandrine-induced apoptosis; inhibition of ERK1/2 did not. Tetrandrine had significant effects on tumors including slower growth and longer animal survival time and higher survival rate. Higher dose and earlier treatment were more effective than lower dose and delayed treatment. TUNEL staining showed prominent tetrandrine-induced apoptosis of tumors. These data suggest that tetrandrine induced significant apoptosis of cultured and subcutaneous CT-26 cells. Tetrandrine-induced apoptosis might be at least partially related to activation of the p38 MAPK signaling pathway. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19586712     DOI: 10.1016/j.canlet.2009.06.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  36 in total

1.  Tetrandrine inhibits Wnt/β-catenin signaling and suppresses tumor growth of human colorectal cancer.

Authors:  Bai-Cheng He; Jian-Li Gao; Bing-Qiang Zhang; Qing Luo; Qiong Shi; Stephanie H Kim; Enyi Huang; Yanhong Gao; Ke Yang; Eric R Wagner; Linyuan Wang; Ni Tang; Jinyong Luo; Xing Liu; Mi Li; Yang Bi; Jikun Shen; Gaurav Luther; Ning Hu; Qixin Zhou; Hue H Luu; Rex C Haydon; Yingming Zhao; Tong-Chuan He
Journal:  Mol Pharmacol       Date:  2010-10-26       Impact factor: 4.436

2.  Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine.

Authors:  Su Li; Zhaoshuai Ji; Meijuan Zou; Xin Nie; Yijie Shi; Gang Cheng
Journal:  AAPS PharmSciTech       Date:  2011-08-03       Impact factor: 3.246

3.  JNK/AP-1 activation contributes to tetrandrine resistance in T-cell acute lymphoblastic leukaemia.

Authors:  Jun-Ting Liou; Chin-Sheng Lin; Yu-Cheng Liao; Ling-Jun Ho; Shih-Ping Yang; Jenn-Haung Lai
Journal:  Acta Pharmacol Sin       Date:  2017-06-12       Impact factor: 6.150

4.  [Screening of drugs that selectively inhibit uveal melanoma cells with SF3B1 mutations].

Authors:  X Luo; C Ren; X Liu; G Zhang; S Huang; L Yu; Y Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-12-20

5.  Tetrandrine Inhibits Epithelial-Mesenchymal Transition in IL-6-Induced HCT116 Human Colorectal Cancer Cells.

Authors:  Shih-Chang Tsai; Wei-Chei Wu; Jai-Sing Yang
Journal:  Onco Targets Ther       Date:  2021-08-21       Impact factor: 4.147

6.  Autophagy-related gene 7 (ATG7) and reactive oxygen species/extracellular signal-regulated kinase regulate tetrandrine-induced autophagy in human hepatocellular carcinoma.

Authors:  Ke Gong; Chao Chen; Yao Zhan; Yan Chen; Zebo Huang; Wenhua Li
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

7.  Tetrandrine triggers apoptosis and cell cycle arrest in human renal cell carcinoma cells.

Authors:  Tao Chen; Bing Ji; Yancui Chen
Journal:  J Nat Med       Date:  2013-04-06       Impact factor: 2.343

Review 8.  Research Progress on Reversing Multidrug Resistance in Tumors by Using Chinese Medicine.

Authors:  Huan-Dong Zhao; Hong-Juan Xie; Jian Li; Cai-Ping Ren; Yu-Xiang Chen
Journal:  Chin J Integr Med       Date:  2018-06-02       Impact factor: 1.978

9.  Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer.

Authors:  Xiaolin Li; Hua'e Xu; Xinzheng Dai; Zhenshu Zhu; Baorui Liu; Xiaowei Lu
Journal:  Int J Nanomedicine       Date:  2012-10-02

10.  Alkaloids isolated from natural herbs as the anticancer agents.

Authors:  Jin-Jian Lu; Jiao-Lin Bao; Xiu-Ping Chen; Min Huang; Yi-Tao Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-04       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.